Case Studies  /  Portfolio, Licensing and Development

Identifying high value global in-licensing targets in the RNA/ASO space


  • A top pharmaceutical company sought to evaluate emerging approaches in intracellular delivery and tissue-specific targeting of RNA/ASO molecules
  • The client needed to understand corporate and venture fund investment patterns
  • Ultimately, the client wanted to inform an important acquisition


  • Conducted a comprehensive market evaluation of emerging RNA/ASO delivery technologies with a focus on GalNac targeting and other receptor-mediated approaches
  • Compared the assets using competitive grids and flagged differentiating features
  • Profiled licensing and partnership activity and identified unpartnered assets


  • Our team produced a rapid-turnaround, comprehensive landscape evaluation including key challenges and potentially disruptive approaches
  • Our client used this analysis to inform a key partnership (>$225 MM)

© 2024 Opus Strategy, LLC